SCHEDULE 13G/A: Samsara BioCapital Amends Passive Stake in IO Biotech, Reports 3.8% Ownership
Ownership Disclosure Amendment
Samsara BioCapital, L.P., along with its general partner and managing member, filed an amended Schedule 13G indicating a 3.8% passive ownership stake in IO Biotech, Inc. as of December 31, 2024.
Summary
- Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, and Srinivas Akkaraju (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in IO Biotech, Inc.
- As of December 31, 2024, the Reporting Persons collectively beneficially own 2,631,578 shares of IO Biotech, Inc. common stock.
- This ownership represents 3.8% of the total class of securities outstanding.
- The beneficial ownership includes warrants exercisable for up to 2,631,578 shares of common stock.
- The percentage of class is calculated based on 65,880,914 shares of common stock outstanding as of November 8, 2024, plus the 2,631,578 shares issuable upon warrant exercise.
- The Reporting Persons hold shared voting and shared dispositive power over these shares.
- The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual, routine regulatory filing disclosing beneficial ownership. It contains no positive or negative operational or financial news about the issuer, thus maintaining a neutral sentiment.
Positives
- The filing clarifies a significant passive investment by Samsara BioCapital, indicating continued investor interest in IO Biotech, Inc.
- The explicit statement that the investment is not for the purpose of changing or influencing control provides stability regarding corporate governance.
Risks
- The document does not detail specific risks related to IO Biotech, Inc.'s operations or financial health, as it is an ownership disclosure filing.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding IO Biotech, Inc.'s future performance or strategic direction.
Management Comments
- Srinivas Akkaraju, Managing Member of Samsara BioCapital GP, LLC, signed the filing on behalf of all Reporting Persons, certifying the accuracy of the information and the passive nature of the investment.
Industry Context
This filing is a routine disclosure in the biotechnology sector, where investment funds frequently take passive stakes in publicly traded companies. It reflects a standard compliance requirement for significant ownership positions, indicating ongoing investor interest in the company's potential.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant passive investor's stake, confirming that the investment is not intended to influence control of the company.
Key Dates
| Date | Description |
|---|---|
| 2024-11-08 | Date as of which IO Biotech, Inc.'s common stock outstanding (65,880,914 shares) was reported in its Form 10-Q. |
| 2024-12-31 | Date of event which requires the filing of this statement (beneficial ownership snapshot date). |
| 2025-02-14 | Date the Schedule 13G/A was signed and filed. |
Keywords
IO Biotech, Samsara BioCapital, Schedule 13G/A, Beneficial Ownership, Common Stock, Warrants, Passive Investment, SEC Filing, Biotechnology, Investment Fund
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.